JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy
  • Search
  • Contact Us
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win

  • Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care

  • Lilly’s Once-Daily Oral GLP-1 Pill Shows Promise for Type 2 Diabetes

  • Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race

  • Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk

  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial

  • Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval

  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials

  • New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo

  • You are here:  
  • Home
  • Tags
  • Orforglipron
 

JCS/T2D

We are advocates. We learn. We share. We inform.
Bringing clarity to type 2 diabetes, obesity care, health research, and the data behind them.

Content is provided for educational and informational purposes and is not medical advice.

Helpful Links

About Us
Contact Us
JCS Analytics

Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.